Logo image of RLAY

RELAY THERAPEUTICS INC (RLAY) Stock Fundamental Analysis

NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD

2.75  +0.06 (+2.23%)

After market: 2.75 0 (0%)

Fundamental Rating

4

RLAY gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While RLAY has a great health rating, there are worries on its profitability. RLAY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RLAY has reported negative net income.
In the past year RLAY has reported a negative cash flow from operations.
RLAY had negative earnings in each of the past 5 years.
In the past 5 years RLAY always reported negative operating cash flow.
RLAY Yearly Net Income VS EBIT VS OCF VS FCFRLAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -38.76%, RLAY is in line with its industry, outperforming 57.57% of the companies in the same industry.
RLAY has a Return On Equity of -43.42%. This is in the better half of the industry: RLAY outperforms 68.31% of its industry peers.
Industry RankSector Rank
ROA -38.76%
ROE -43.42%
ROIC N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
RLAY Yearly ROA, ROE, ROICRLAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RLAY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLAY Yearly Profit, Operating, Gross MarginsRLAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

7

2. Health

2.1 Basic Checks

RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RLAY has more shares outstanding
RLAY has more shares outstanding than it did 5 years ago.
RLAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RLAY Yearly Shares OutstandingRLAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RLAY Yearly Total Debt VS Total AssetsRLAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.16, we must say that RLAY is in the distress zone and has some risk of bankruptcy.
RLAY has a Altman-Z score of -0.16. This is in the better half of the industry: RLAY outperforms 63.91% of its industry peers.
RLAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.16
ROIC/WACCN/A
WACC10.21%
RLAY Yearly LT Debt VS Equity VS FCFRLAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 15.95 indicates that RLAY has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 15.95, RLAY belongs to the top of the industry, outperforming 92.25% of the companies in the same industry.
RLAY has a Quick Ratio of 15.95. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
RLAY has a better Quick ratio (15.95) than 92.25% of its industry peers.
Industry RankSector Rank
Current Ratio 15.95
Quick Ratio 15.95
RLAY Yearly Current Assets VS Current LiabilitesRLAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

RLAY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.64%, which is quite good.
RLAY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.42%.
Measured over the past years, RLAY shows a very strong growth in Revenue. The Revenue has been growing by 48.92% on average per year.
EPS 1Y (TTM)14.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.84%
Revenue 1Y (TTM)-80.42%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RLAY will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.38% on average per year.
Based on estimates for the next years, RLAY will show a very strong growth in Revenue. The Revenue will grow by 83.83% on average per year.
EPS Next Y11.31%
EPS Next 2Y2.1%
EPS Next 3Y-0.26%
EPS Next 5Y14.38%
Revenue Next Year-72.86%
Revenue Next 2Y18.82%
Revenue Next 3Y16.39%
Revenue Next 5Y83.83%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RLAY Yearly Revenue VS EstimatesRLAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RLAY Yearly EPS VS EstimatesRLAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
Also next year RLAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLAY Price Earnings VS Forward Price EarningsRLAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLAY Per share dataRLAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.1%
EPS Next 3Y-0.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RLAY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RELAY THERAPEUTICS INC

NASDAQ:RLAY (4/21/2025, 8:00:01 PM)

After market: 2.75 0 (0%)

2.75

+0.06 (+2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-01 2025-05-01/amc
Inst Owners82.86%
Inst Owner Change0.01%
Ins Owners1.92%
Ins Owner Change2.46%
Market Cap466.18M
Analysts86.32
Price Target20.3 (638.18%)
Short Float %11.83%
Short Ratio7.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.5%
Min EPS beat(2)19.53%
Max EPS beat(2)21.46%
EPS beat(4)4
Avg EPS beat(4)15.61%
Min EPS beat(4)7.69%
Max EPS beat(4)21.46%
EPS beat(8)7
Avg EPS beat(8)12.57%
EPS beat(12)9
Avg EPS beat(12)9.64%
EPS beat(16)10
Avg EPS beat(16)-14.85%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)3053.38%
Min Revenue beat(4)-100%
Max Revenue beat(4)12513.5%
Revenue beat(8)3
Avg Revenue beat(8)2332.03%
Revenue beat(12)4
Avg Revenue beat(12)1545.81%
Revenue beat(16)5
Avg Revenue beat(16)1175.79%
PT rev (1m)-4.33%
PT rev (3m)-7.44%
EPS NQ rev (1m)5.61%
EPS NQ rev (3m)16.82%
EPS NY rev (1m)21.19%
EPS NY rev (3m)21.14%
Revenue NQ rev (1m)11.1%
Revenue NQ rev (3m)-81.48%
Revenue NY rev (1m)19.97%
Revenue NY rev (3m)19.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 46.59
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-2.12
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.06
BVpS4.59
TBVpS4.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.76%
ROE -43.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.93%
Cap/Sales 20.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.95
Quick Ratio 15.95
Altman-Z -0.16
F-Score3
WACC10.21%
ROIC/WACCN/A
Cap/Depr(3y)111.54%
Cap/Depr(5y)95.45%
Cap/Sales(3y)230.95%
Cap/Sales(5y)161.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.84%
EPS Next Y11.31%
EPS Next 2Y2.1%
EPS Next 3Y-0.26%
EPS Next 5Y14.38%
Revenue 1Y (TTM)-80.42%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-72.86%
Revenue Next 2Y18.82%
Revenue Next 3Y16.39%
Revenue Next 5Y83.83%
EBIT growth 1Y43.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.14%
EBIT Next 3Y-14.87%
EBIT Next 5Y8.81%
FCF growth 1Y17.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.05%
OCF growth 3YN/A
OCF growth 5YN/A